Deals channel feed – Endpoints News

Deals channel feed

Novartis signs off on $20B deal to sell Roche stake, acquired 20 years ago, back to cross-town rival

4 years ago

Flagship and the Cystic Fibrosis Foundation team up on a novel research pact to chase down potential cures

4 years ago

As anti-inflammatory space heats up, Pfizer spins JAK, TYK2 drugs into new startup

4 years ago

Novartis enlists transatlantic startup to discover new protein degraders in $1.3B+ deal

4 years ago

Moderna tries its hand at CRISPR through a new development pact with Metagenomi

4 years ago

Merck dives even further into cytokine research as deal spree continues

4 years ago

AstraZeneca sells two COPD drugs to a familiar partner as Pascal Soriot's oncology push marches on

4 years ago

Merck delays $11.5B Acceleron buyout to give antitrust watchdog 'additional time for review'

4 years ago

Scoop: Eli Lilly and AC Immune quietly scrapped Alzheimer’s studies for the centerpiece of $2B deal months ago

4 years ago

Takeda swoops in and scoops up a cell therapy startup in buyout deal, expanding oncology pipeline

4 years ago

With Covid-19 vaccine in limbo, China's Fosun inks $628M deal for a Prevnar 13 rival

4 years ago

Jennifer Doudna spinout inks a Mammoth CRISPR deal with Vertex worth nearly $700M

4 years ago

The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties

4 years ago

With Sandoz continuing to drag on Novartis, Vas Narasimhan says he may finally be ready for a sale or spinoff

4 years ago

After passing on Acceleron, Bristol Myers eyes bolt-on acquisition of autoimmune specialist — report

4 years ago

As AI continues to entice Big Pharma, a Carlyle-led drugmaker syndicate shells out $430M for cloud computing player

4 years ago

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report

4 years ago

Hedge fund jumps in with Avoro activists in an attempt to derail Merck's $11B Acceleron buyout

4 years ago

'No excuse': ICER determines AstraZeneca's new moneymaker Soliris is vastly overpriced

4 years ago

Takeda, Wave Life Sciences revise their $230M R&D collaboration, dropping discovery work

4 years ago

Still reeling from PhII failure, Calithera beefs up its oncology portfolio with a little help from Takeda

4 years ago

A Bob Nelsen startup turns to Harvard to help sharpen its tech, inspiring first spinout

4 years ago

This midwestern CDMO just picked up 3 acquisitions in less than a week

4 years ago

A California biotech steps into the viral vector space with new site build of $75M

4 years ago

First page Previous page 67 68 697071 72 73 Next page Last page